Dr. McGilvray studied medicine at McGill University, graduating in 1993. He entered the General Surgery training program at the University of Toronto that same year. During his residency, he undertook graduate studies in Dr. Ori Rotstein’s laboratory and obtained a PhD in Cell Biology. He became a Fellow of the Royal College of Physicians and Surgeons of Canada in 2001. After a clinical fellowship in Transplantation and Hepatobiliary Surgery at the Toronto General Hospital, he began his appointment at the University Health Network in 2003. He is currently an Associate Professor in the Department of Surgery at the University of Toronto.
- Diseases of the liver, particularly viral hepatitis
- Transplant immunology
- Hepatic ischemia/reperfusion injury
- Vascular reconstructive techniques for locally advanced liver and pancreas cancer
- Applicability of transplantation to oncology diagnoses
J Vis Commun Med. 2017 Mar 14;:1-6
Liver Transplantation is a Preferable Alternative to Palliative Therapy for Selected Patients with Advanced Hepatocellular Carcinoma.
Ann Surg Oncol. 2017 Feb 03;:
Gold Nanoparticle Uptake by Human Derived Macrophages and Primary Liver Phagocytic Cells is Dependent on Phenotype.
ACS Nano. 2016 Dec 31;:
Curr Opin Organ Transplant. 2016 Dec 21;:
Diet polyphenol curcumin stimulates hepatic Fgf21 production and restores its sensitivity in high fat diet fed male mice.
Endocrinology. 2016 Dec 14;:jc20161596
Am J Transplant. 2016 Aug 22;
Nat Mater. 2016 Aug 15;
Should We Exclude Live Donor Liver Transplantation for Liver Transplant Recipients Requiring Mechanical Ventilation and Intensive Care Unit Care?
Transplant Direct. 2015 Sep;1(8):e30
Plasma phospholipids and fatty acid composition differ between liver biopsy-proven nonalcoholic fatty liver disease and healthy subjects.
Nutr Diabetes. 2016;6(7):e220
Senior Scientist, Toronto General Hospital Research Institute (TGHRI)
Associate Professor, Department of Surgery, Faculty of Medicine, University of Toronto